Browse News
Filter News
Found 96 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
4/2/2024
LENZ Therapeutics, Inc. today announced that the Company will host a conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. ET to discuss the topline results from its Phase 3 CLARITY study, a group of three multi-center, double-masked, randomized active and vehicle-controlled clinical trials evaluating the efficacy and safety of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia.
-
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
3/21/2024
LENZ Therapeutics, Inc. (Nasdaq: LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced the completion of its previously announced merger with Graphite Bio, Inc. (previously trading on Nasdaq under the ticker symbol “GRPH”) (“Graphite Bio”).
-
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
3/8/2024
Graphite Bio, Inc. announced that its Board of Directors has declared a special dividend in connection with the previously announced merger with Lenz Therapeutics, Inc. pursuant to the Agreement and Plan of Merger, dated November 14, 2023.
-
Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases
1/17/2024
Tr1X, Inc. announced its emergence from stealth with a $75 million Series A financing to bring universal allogeneic regulatory T and CAR-Treg cell therapies to the clinic to treat and potentially cure autoimmune and inflammatory diseases.
-
Kamau Therapeutics Emerges from Stealth With Clinical-Stage Novel Gene Correction Technology Targeting Life-Threatening Genetic Diseases
12/7/2023
Kamau Therapeutics ("Kamau" or "the Company"), a clinical-stage gene correction company, announced today its emergence from stealth, following a strategic transaction with Graphite Bio (“Graphite”).
-
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
11/15/2023
LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ: GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
-
Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer
10/17/2023
Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, announced that Weston Miller, M.D., will join the company as chief medical officer effective October 23, 2023.
-
Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors
10/10/2023
Pacira BioSciences, Inc., the industry leader in its commitment to non-opioid pain management and regenerative health solutions, announced the appointments of Marcelo Bigal, MD, PhD, Abraham Ceesay, Michael Yang, and Alethia Young, to its Board of Directors effective immediately.
-
Biogen Appoints Jane Grogan as Head of Research
9/6/2023
Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023.
-
Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/3/2023
Bicycle Therapeutics Limited plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate updates.
-
Graphite Bio Announces Departure of Chief Financial Officer
6/23/2023
Graphite Bio, Inc. (Nasdaq: GRPH) today announced that Alethia Young, the Company’s Chief Financial Officer, will step down from her position to pursue other opportunities.
-
Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer
6/23/2023
Bicycle Therapeutics plc today announced the appointment of Alethia Young as its new Chief Financial Officer, effective July 17th.
-
Data show the potential of Editas’ sickle cell disease and transfusion-dependent beta thalassemia gene therapy candidate, but it might not be enough to overtake Vertex and CRISPR Therapeutics.
-
Siren Biotechnology Launches to Pioneer Universal AAV Immuno-Gene Therapy™ for Cancer
5/17/2023
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy, a revolutionary new treatment modality for cancer, launched out of stealth concurrent with its first preclinical data presentation at the ASGCT 26th Annual Meeting, taking place in Los Angeles, May 16-20th.
-
Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results
5/10/2023
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and first-quarter 2023 financial results.
-
Kronos Bio Announces Changes to Board of Directors
4/11/2023
Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced the appointment of Katherine Vega Stultz to its Board of Directors, replacing Otello Stampacchia, Ph.D., who stepped down as of March 31, 2023.
-
In an earnings call Wednesday, bluebird bio revealed it is unlikely to meet its first-quarter goal to submit a Biologics License Application for sickle cell disease (SCD) gene therapy lovo-cel.
-
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
3/20/2023
Graphite Bio, Inc. (Nasdaq: GRPH) today reported recent business progress and fourth quarter and fiscal year 2022 financial results.
-
The hits kept coming for the sickle cell disease space last week as the FDA placed a full clinical hold on Fulcrum Therapeutics’ Investigational New Drug application FTX-6058.